Unicycive Therapeutics, Inc. Share Price & Technical Analysis
UNCY · $7.06 (-12.62%)
Healthcare / Biotechnology
$7.06
-12.62%
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester deriva…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
-9% return in May, -9% avg return in past 3 year May month.
26% return in 2026, 84% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 3% | 15% | 0% | 17% | -9% | – | – | – | – | – | – | – | 26% |
| 25 | -24% | -7% | 9% | 8% | -11% | -19% | -14% | -2% | 5% | 14% | 38% | -9% | -10% |
| 24 | 9% | 45% | -3% | -19% | -24% | -44% | -19% | -23% | 24% | 26% | 25% | 10% | 7% |
| 23 | 8% | -12% | 304% | -40% | 8% | -4% | -8% | -36% | 13% | -37% | -11% | 71% | 255% |
| 22 | -33% | -3% | -3% | -33% | -1% | -7% | -11% | -5% | -13% | 15% | 4% | -25% | -115% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Emerging · Neutral
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$211.06M
P/E ratio
—
52W high
$11.00
52W low
$3.71
Volume
16,06,639
Beta
1.77
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Unicycive Therapeutics, Inc. share price today?
- Unicycive Therapeutics, Inc. (UNCY) last traded around $7.06 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does UNCY have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for UNCY. Download the app for real-time alerts.
- How can I analyze Unicycive Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.